Top Page
RemeGen Co. Ltd. Class H
(9995)
RemeGen Co. Ltd. Class H (9995) vs. iShares MSCI Hong Kong ETF (EWH)
RemeGen Co. Ltd. Class H Business Overview & Revenue Model
RemeGen Co. Ltd. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.07B | 1.72B | 1.08B | 767.77M | 1.42B | 0.00 |
| Gross Profit | 1.72B | 1.37B | 822.99M | 497.84M | 1.36B | 0.00 |
| EBITDA | -839.66M | -1.19B | -1.25B | -805.70M | 402.05M | -661.56M |
| Net Income | -1.14B | -1.47B | -1.51B | -997.84M | 276.26M | -727.09M |
Balance Sheet | ||||||
| Total Assets | 5.85B | 5.50B | 5.53B | 6.02B | 4.16B | 4.12B |
| Cash, Cash Equivalents and Short-Term Investments | 1.28B | 759.53M | 709.07M | 2.19B | 1.76B | 2.77B |
| Total Debt | 2.67B | 2.67B | 1.26B | 165.03M | 102.78M | 197.69M |
| Total Liabilities | 3.49B | 3.51B | 2.09B | 1.04B | 712.79M | 523.07M |
| Stockholders Equity | 2.36B | 1.99B | 3.44B | 4.98B | 3.45B | 3.59B |
Cash Flow | ||||||
| Free Cash Flow | -783.71M | -1.38B | -2.35B | -2.02B | -353.71M | -1.14B |
| Operating Cash Flow | -539.67M | -1.11B | -1.50B | -1.26B | 263.63M | -660.08M |
| Investing Cash Flow | -32.71M | -248.24M | -817.65M | -841.56M | -637.95M | -479.06M |
| Financing Cash Flow | 1.17B | 1.39B | 978.31M | 2.43B | -626.90M | 3.90B |
RemeGen Co. Ltd. Class H Technical Analysis
RemeGen Co. Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$35.22B | 39.57 | 27.37% | ― | 2.57% | 18.79% | |
60 Neutral | HK$29.36B | -20.65 | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | HK$37.15B | -23.40 | -15.06% | ― | 39.02% | 48.26% | |
42 Neutral | HK$15.98B | -9.41 | -30.41% | ― | 23.87% | 30.08% | |
40 Underperform | HK$50.06B | -41.85 | -39.64% | ― | 46.14% | 39.56% |
RemeGen Co. Ltd. Class H Corporate Events
RemeGen Co., Ltd. recently held its 2025 third extraordinary general meeting (EGM) where key resolutions were passed. The meeting saw a significant turnout with 47.58% of shares represented. Key resolutions included the approval of expected day-to-day related party transactions for 2026 to 2028 and amendments to several governance policies. These decisions are poised to influence the company’s operational strategies and governance structure, potentially impacting its market position and stakeholder relations.
RemeGen Co., Ltd. has announced the convening of its 2025 third extraordinary general meeting (EGM) scheduled for December 2, 2025. The meeting will address resolutions concerning related party transactions for 2026 to 2028 and amendments to several governance policies, which could impact the company’s operational and strategic framework.
RemeGen Co., Ltd. has announced a discloseable transaction involving the purchase of a principal-guaranteed wealth management product worth RMB400 million from SPDB Yantai Branch. This transaction, along with a prior agreement made in October 2025, is part of the company’s strategy to utilize idle self-owned funds for cash management, reflecting a cautious approach to financial management amidst market fluctuations. The purchase is subject to reporting and announcement requirements under the Hong Kong Listing Rules due to the aggregated transaction value exceeding 5% of the applicable percentage ratios.
RemeGen Co., Ltd. has released its unaudited 2025 third quarterly report, prepared according to Chinese accounting principles and the STAR Market requirements of the Shanghai Stock Exchange. The report, which has been reviewed by the audit committee but not by independent auditors, emphasizes the company’s commitment to transparency and accuracy in its financial disclosures, advising shareholders and potential investors to exercise caution when dealing with its securities.
RemeGen Co., Ltd. has announced the renewal of several connected transactions, including the MabPlex Master Service Agreement and the Materials Purchase Framework Agreement, extending their terms from 2026 to 2028. These transactions, which involve key stakeholders such as MabPlex and RC Pharma, are crucial for the company’s continued operations and strategic partnerships. Additionally, the company plans to adjust its leasing agreements by increasing equipment leases and reducing building and apartment leases, reflecting its business expansion and changing demand.
RemeGen Co., Ltd. has announced that its board of directors will convene on October 30, 2025, to review and approve the company’s unaudited third-quarter results for the period ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market position and stakeholder interests.
RemeGen Co., Ltd. has announced a discloseable transaction involving the purchase of wealth management products from SPDB Yantai Branch, utilizing idle self-owned funds and raised proceeds. The transaction involves a total investment of RMB500 million, with the aim of optimizing cash management and potentially enhancing financial returns through principal-guaranteed products linked to the EUR-USD exchange rate. This move is subject to reporting and announcement requirements under the Hong Kong Listing Rules, reflecting the company’s strategic financial management efforts.